Orexins are peptides produced by lateral hypothalamic neurons that exert a prominent role in the maintenance of wakefulness by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptors located in wake-active structures. Pharmacological blockade of both receptors by the dual OX1/2R antagonist (2R)-2-[(1S)-6,7-Dimethoxy-1-{2-[4- 
Introduction
The neuropeptides orexins (orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2), which are produced by a cluster of neurons within the lateral posterior hypothalamus (de Lecea et al., 1998; Sakurai et al., 1998) , project widely throughout the brain and play a major role in the regulation of sleep-wake states (Hagan et al., 1999) .
Activation of orexin neurons contributes to the maintenance of wakefulness and endogenous loss of orexin neurons in humans results in narcolepsy, a condition characterized by excessive sleepiness, hypnagogic hallucinations, and cataplexy (Zeitzer et al., 2006) . Orexins mediate their effect by stimulating two closely related G-protein coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptors located in wakeactive monoaminergic and cholinergic systems (Peyron et al., 1998; Sakurai et al., 1998; Marcus et al., 2001) . It has thus been hypothesized that blockade of orexin receptors would be a novel pharmacological approach for the treatment of insomnia. Recently, it was reported that pharmacological blockade of both receptors by the dual OX1/2R antagonist almorexant promoted sleep in rats, dogs and humans during their respective active period (Brisbare-Roch et al., 2007) .
Interestingly, OX1R and OX2R are differentially distributed in brain areas that regulate sleep and wake, including the tuberomammillary nucleus, locus coeruleus, dorsal raphe and laterodorsal tegmental/pedonculopontine tegmental nuclei (Sakurai et al., 1998; Marcus et al., 2001) . Within the monoaminergic system, locus coeruleus neurons exclusively express OX1R.
In contrast, OX2R are densely located in the tuberomammillary nucleus, whereas dorsal raphe neurons express both OX1R and
OX2R. It has been demonstrated that the arousal effect of orexin-A depended on JPET #152009
6 histaminergic activation via OX2R in the tuberomammillary nucleus (Eriksson et al., 2001; Huang et al., 2001 ). The wake-promoting effect of orexin-A was reduced by pretreatment with the histamine-H1 receptor antagonist pyrilamine in rats (Yamanaka et al., 2002) , and virtually absent in mice lacking H1 receptors (Huang et al., 2001 ). OX1R
in the locus coeruleus have been shown to regulate rapid eye movement (REM) sleep. In rats, local administration of orexin-A into the locus coeruleus suppressed REM sleep (Bourgin et al., 2000) , and the selective OX1R antagonist 1-(2-Methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea (SB-334867) could reverse the REM sleep suppression induced by intracerebroventricular injection of orexin-A (Smith et al., 2003) .
Significantly, investigators have also examined how the targeted disruption in the genes encoding the two orexin receptors influence the states of vigilance. Double OX1R
and OX2R knockout mice display wake disturbances resembling human narcolepsy (Willie et al., 2001) , characterized by excessive daytime sleepiness that can be accompanied by the sudden loss of muscular tone (cataplexy). While a narcoleptic phenotype was not documented in the OX1R knockout mouse (Willie et al., 2001 ), OX2R knockout mice developed a mild disruption in wake patterns (Willie et al., 2003) .
Taken together, these studies provide evidence that OX1R and OX2R may have a differential impact in the modulation of the sleep-wake states. The recent availability of selective antagonists of OX1R (SB-408124) (Langmead et al., 2004) antagonists correlated with a decrease in hypothalamic histamine (HA) release. The most striking finding is that additional blockade of OX1R greatly attenuated this hypnotic activity, possibly mediated by a transient increase in dopaminergic neurotransmission.
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Methods

Animals
All the studies were carried out in male Sprague-Dawley rats (Charles River
Laboratories, weighing 300-350 g). Animals were housed individually under controlled conditions with a 12:12 light/dark schedule (lights on at 6 AM) and temperature (22 ± 2ºC) and allowed unrestricted access to food and water. All in vivo procedures detailed in this investigation were implemented in accordance with policies established by the Guide for the Care and Use of Laboratory Animals as adopted by the United States National Institutes of Health.
Ex vivo OX1R and OX2R binding autoradiography
Animals were treated by subcutaneous administration of vehicle, almorexant (3 or 30 mg/kg), JNJ-10397049 (0.3, 3 or 30 mg/kg) or SB-408124 (30 mg/kg). The animals were euthanized at different time points (0.25 h, 0.5 h, 1 h, 2 h, 4 h and 6 h, n=3 to 6 animals per time point) using carbon dioxide and decapitated after drug administration.
Tissue sections for ex vivo receptor autoradiography were prepared as previously described (Langlois et al., 2001) . Ex vivo occupancy of OX1R and OXR2 binding site was measured in the tenia tecta (OX1R) and frontal cortex (OX2R) of each individual rat.
After thawing, the sections were dried under a stream of cold air and then incubated at room temperature for 10 min in Tris, 10 mM MgCl, 5 mM EDTA buffer with the tracer.
(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) (SB-674042) was used (Langmead et al., 2004 (toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl acetamide (EMPA) was used (Malherbe et al., 2009 ). The sections were not washed prior to incubation, to avoid dissociation of the drug-receptor complex. Incubation was restricted to 10 min at room temperature to minimize dissociation of the drug from the receptor. Nonspecific binding was determined in the presence of 10 μM SB-408124 for OX1R or JNJ-10397049 for OX2R. After the incubation, the slides were washed in ice-cold buffer (Tris, 10 mM MgCl, 5 mM EDTA buffer), followed by a quick rinse in ice-cold water. The sections were then dried under a stream of cold air. Quantitative analysis was performed as previously described (Langlois et al., 2001 ) using a β-imager (BioSpace, Paris, France).
Ex vivo receptor labeling was expressed as the percentage of receptor labeling in corresponding brain areas of saline-treated animals. The percentage of receptor occupancy was plotted against time.
Sleep recording and analysis
For the determination of polysomnographic waveforms, two stainless steel screw electrodes in the frontal and parietal cortex for the electroencephalogram (EEG) and wire electrodes in dorsal nuchal muscles for the electromyogram (EMG) were implanted in each rat under isofluorane anesthesia. Electrodes were connected to a sterile two-channel International). High and low pass filters were set at 1 and 30 Hz, respectively, for the EEG signal and at 30 and 100 Hz, respectively, for the EMG signal.
Using the computer program SleepSign (Kissei Comtec, Nagano, Japan), consecutive EEG/EMG recordings were divided into individual 10-second epochs that were then visually assigned vigilance states based upon conventional criteria for wake, non-rapid eye movement (NREM) sleep and REM sleep as described previously was held on the B:A ratio of 100:0 for 1.5 min. The linear gradient was changed over the next 0.5 min to B:A ratio of 5:95 and held for 2.5 min, then returned to the starting conditions. The total run time was 6.5 min and flow rate was 0.6 ml/min (Shimadzu LC-10AD VP with SCL-10A VP system controller). Tandem mass spectrometric (MS/MS) detection was carried out on a PE Sciex API4000 in the positive ion mode (ESI) by multiple reaction monitoring (MH+/daughter was 112.09 ® 95.1 m/z). Dialysis experiments for DA, NE and 5-HT were performed using HPLC/ECD as previously described (Barbier et al., 2007) .
The concentration for each sample was calculated from the peak area of the chromatographic signal and the slope from the corresponding analytes standard curve. Statistics (paired t-test) were calculated using Prism software (GraphPad, San Diego, CA). A one compartmental pharmacokinetic model was also applied to these data using the software package WinNonlin Version 4.0.1. (Pharsight, Palo Alto, Ca). The model that was employed was a one compartment first order, no lag time, first order elimination model (Model 3). The parameters of the model were optimized using least squares non-linear regression. Pharmacokinetic parameters (C max ) are given as the means ± CV%. The CV% is a measure of dispersion of a probability distribution. It is defined as the ratio of the standard deviation to the mean. The CV% was calculated as the ratio of the standard error for each parameter to its estimated value.
This article has not been copyedited and formatted. The final version may differ from this version. 
Promotion of sleep induced by selective OX2R antagonism vs. dual OX1/2R
blockade in rats.
To investigate the specific role of OX1R and OX2R in sleep modulation, we compared the effects of selective or dual antagonists at each receptor subtype. The selective OX2R
antagonist JNJ-10397049 (0.3, 3, and 30 mg/kg), the dual OX1/2R antagonist almorexant (3 and 30 mg/kg) and the selective OX1R antagonist SB-408124 (30 mg/kg) were s.c.
administered at 2 hours into the light phase in rats. At this point in the light-dark cycle, the diurnal concentrations of the orexin-A peptide are still relatively elevated but are starting to rapidly wane (Yoshida et al., 2001) , whereas the sleep pressure is relatively high. For this facet of the study, sleep-wake parameters were presented for the first 2-hour period following dosing based on the short-lasting sleep-promoting effect observed in these conditions. This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A) . In contrast, the OX2R and OX1/2R antagonists induced an equipotent decrease in REM sleep latency at the highest dose tested (30 mg/kg) (Fig. 2B) . Both compounds produced a significant increase in NREM sleep time, the OX2R antagonist from the dose of 3 mg/kg onwards and the OX1/2R antagonist at the highest dose tested only (Fig. 2C ). In addition, at the 30 mg/kg dose REM sleep time was significantly increased following the OX1/2R
antagonist administration, while a non-significant increase was also measured in rats treated with the OX2R antagonist (Fig. 2D ). The increase in NREM sleep time produced by the OX2R antagonist was due to a prolongation of NREM bouts with no alteration in the bout numbers. In contrast, the NREM and REM sleep time-increasing effect following the OX1/2R antagonist treatment was apparently due to an enhancement in the number of NREM and REM sleep bouts with no change in their duration. However, this discrepancy was rather due to the significant lower number of NREM bouts with vehicle almorexant (OX1/2R) as compared to vehicle JNJ-10397049 (OX2R) and vehicle SB-408124 (OX1R) ( (Fig. 2) .
In a subsequent investigation, the OX2R antagonist (3 and 30 mg/kg), the OX1/2R antagonist (3 and 30 mg/kg) and the OX1R antagonist (30 mg/kg) were tested at the onset of the dark (active) phase of the rat. At this time, the diurnal rhythm of the orexin-A peptide starts to increase (Yoshida et al., 2001) while the sleep pressure is at its nadir. For this aspect of the study, the data were garnered from the 12 hours of the dark phase. Similar to our findings during the light phase, the OX2R antagonist elicited a significant dose-dependent reduction in the latency to NREM sleep although a nonsignificant trend existed for the OX1/2R antagonist (Fig. 3A) . In contrast, these compounds did not alter the latency to the first episode of REM sleep (Fig. 3B) . In comparison to vehicle treated animals, the administration of the OX2R antagonist produced a significant prolongation of NREM sleep time during the 12-h dark phase at both 3 and 30 mg/kg whereas the OX1/2R antagonist was able to produce a significant increase in NREM sleep time only at the highest dose tested (30 mg/kg) (Fig. 3C ). For both compounds, the increased NREM sleep time was the result of an enhancement in the number of NREM bouts with no change in their mean duration (Table 1 ). In addition, rats treated with 30 mg/kg of the OX2R or the OX1/2R antagonist exhibited a significant increase in REM sleep time (Fig. 3D ) due to a prolonged mean duration of REM bouts with no change in their numbers (Table 1) . As found after the light phase treatment, the OX1R antagonist did not affect the initiation and the duration of NREM and REM sleep during the dark phase (Fig. 3) .
This article has not been copyedited and formatted. The final version may differ from this version. antagonist displayed a slight but significant decrease in activity counts, and rats administered with the 30 mg/kg dose of the OX1/2R antagonist showed a moderate decrease in body temperature (Fig. 4B ).
Co-administration of a selective OX1R antagonist attenuates the sleep-promoting effects evoked by a selective OX2R antagonist in rats.
This article has not been copyedited and formatted. The final version may differ from this version. In order to try and mirror the actions of the dual OX1/2 receptor antagonist on the sleepwake profile in rats, a study was undertaken in which rats received a selective OX1R
antagonist and a selective OX2R antagonist in combination. For this investigation, rats were co-administered SB-408124 (30 mg/kg) and JNJ-10397049 (10 mg/kg) at 2 hours into the light phase. Administration of the OX2R antagonist alone induced a significant reduction in NREM sleep latency and an increase in NREM sleep duration during the first 2 hours after administration relative to vehicle treatment. Similar to our previous findings, the OX1R antagonist alone caused no change in any sleep parameters.
Interestingly, when the OX1R antagonist was co-administered with the OX2R antagonist the sleep-inducing effect produced by the selective OX2R antagonist alone was partially attenuated (Fig. 5A ) whereas the increase in NREM sleep duration was completely abolished (Fig. 5C ). In contrast, rats receiving the combined therapy entered in REM sleep significantly faster (Fig. 5B) while the overall time spent in REM sleep exhibited a non-significant increase (Fig. 5D ).
To demonstrate that the diminished effect of the OX2R antagonist JNJ-10397049 in the presence of the OX1R antagonist SB-408124 is the result of a pharmacodynamic effect rather than a pharmacokinetic interaction, a drug-drug interaction study between these two compounds was carried out. The results from the drug-drug interaction study indicated that the OX2R antagonist plasma and brain exposure were not decreased by the co-administration of the OX1R antagonist ( 
Effect of orexin receptor blockade on the release of monoamines in various rat brain regions.
As part of our comparative neurochemical profile of the three differential OXR antagonists, the effects of the selective OX2R antagonist JNJ-10397049, the dual OX1/2R antagonist almorexant and the selective OX1R antagonist SB-408124 on monoamine release in defined brain regions were investigated. At 30 minutes prior to the onset of the dark phase, all three compounds were administered s.c. at a dose of 30 mg/kg. Via a microdialysis cannula in freely moving rats, samples for measurement of extracellular release of HA in the LH and DA, NE and 5-HT in the PFC were collected at 30-min intervals during 2 hours before and 4 hours after the injection.
Overall, the two compounds with high affinity for OX2R significantly decreased extracellular HA levels in the LH with a similar magnitude during the first 4 hours following the treatment. In contrast, the OX1R antagonist had no significant effect on extracellular HA release (Fig. 7A) . The two compounds showing high affinity for OX1R elevated DA levels in rat PFC during the dark phase (Fig. 7B ). While the onset was relatively rapid, the elevation in PFC concentrations of DA was short acting with DA levels returning to baseline value at approximately 1 hour following the dual OX1/2R
This article has not been copyedited and formatted. The final version may differ from this version. effects between a selective OX2R antagonist, a dual OX1/2R antagonist and a selective OX1R antagonist that were found either during the light or the dark phase in rats indicate a key role for OX2R. The selective OX2R antagonist showed a 10-fold higher potency than the dual OX1/2 R antagonist in inducing and prolonging sleep whereas the selective OX1R antagonist had no effect. Surprisingly, the dual OX1/2 R antagonist produced less hypnotic activity despite showing slightly higher levels of cortical OX2R occupancy than the selective OX2R antagonist, suggesting that the lower sleep response might be related to its OX1R affinity rather than OX2R occupancy. We tested this hypothesis by coadministrating the two selective OX1R and OX2R antagonists and found that indeed, the blockade of OX1R attenuated the sleep-promoting effects of the OX2R antagonist.
These data, together with the drug-drug interaction results ruling out a possible pharmacokinetic contribution, clearly indicate a functional relationship between OX1R
and OX2R on sleep regulation. It is interesting to note that the additional inhibition of OX1R counteracted the OX2R-induced NREM sleep initiation and prolongation without affecting REM sleep, implying a sleep state specific action. Separate roles for the two OXR subtypes have been postulated that fit well with their distinctive anatomical distribution (Sakurai et al., 1998; Marcus et al., 2001) , namely a specific role in the regulation of REM sleep for OX1R in the locus coeruleus (Bourgin et al., 2000; Smith et al., 2003) and an implication of hypothalamic OX2R in the modulation of NREM sleep (Willie et al., 2003) .
Activation of both OXR subtypes contributes to the physiological control of arousal state (Hagan et al., 1999; Akanmu and Honda, 2005) . In our study, the virtual absence of sleep effect of the OX1R antagonist is in agreement with previous results reporting no significant change in the amount of sleep-wake states after administration of another OX1R antagonist, SB-334867 (Smith et al., 2003) . These data are also in line with the minor sleep alterations (only mild sleep fragmentation) reported in OX1R knockout mice (Sakurai, 2007) . Our observation that the transient concomitant inhibition of both OX1R and OX2R elicited a significantly lesser sleep-promoting effect than the selective blockade of OX2R was unexpected since the double OXR knockout mice display a more pronounced sleep phenotype as compared to the OX2R knockout genotype (Willie et al., 2003) . Furthermore, in human and animal narcolepsy models, orexin deficiency is associated with high prevalence of sleep fragmentation (Shelton et al., 1995; Chemelli et al., 1999; Overeem et al., 2001) . In the present study, selective OX2R or dual OX1/2R antagonism during the dark phase did not cause sleep fragmentation since NREM and REM bout duration was not decreased. On the other hand, during the light phase NREM sleep time was increased after OX2R blockade due to a prolongation of NREM bout duration, which is an index of enhanced sleep consolidation.
Since the measurement of sleep parameters by EEG analysis is the output of a complex, integrated process, we attempted to determine if we could measure more single parameter changes via neurotransmitter microdialysis. We demonstrated for the first time that the sleep-promoting action induced by pharmacological blockade of OX2R by both a selective OX2R antagonist and a dual OX1/2R antagonist paralleled a decrease in extracellular HA release within the LH. Conversely, intracerebroventricular administration of orexin-A has been reported to enhance hypothalamic HA release in rats (Ishizuka et al., 2002) and mice (Huang et al., 2001 ). Collectively, these findings strongly support a major role of the histaminergic system in the arousal effect of orexins (Bayer et al., 2001) . In line with the reduced hypnotic activity of a dual OX1/2R
antagonist relative to a selective OX2R antagonist, the decrease in extracellular HA levels within the LH was associated with a short lasting increase in DA release within the PFC only in rats treated with the dual OX1/2R antagonist. Similarly, this enhancement of extracellular DA levels in the PFC occurred also after administration of the selective OX1R antagonist, and therefore seems to be mediated through OX1R blockade. Since dopaminergic stimulation is associated with arousal, it is possible that the short lasting elevation of extracellular cortical DA levels are responsible for the attenuated hypnotic activity elicited by the dual OX1/2R antagonist, despite its robust OX2R occupancy. In apparent contradiction with these data, orexin-induced hyperlocomotion has been shown to be mediated by the dopaminergic system (Nakamura et al., 2000) and to correlate with increased DA levels in the PFC (Vittoz and Berridge, 2005) . However, DA concentrations in the rat medial PFC are increased not only during wake but also during REM sleep relative to NREM sleep (Lena et al., 2005) , which may partly explain why the blockade of OX1R suppressed the NREM but not the REM sleep-promoting effects induced by OX2R inhibition. While orexin-containing neurons in the ventral tegmental area have been associated with addiction and arousal (de Lecea et al., 2006; Harris and Aston-Jones, 2006) , it is speculated that DA also plays an important role in OXRmediated sleep, particularly REM sleep modulation that needs to be further clarified. In our hands, neither NE nor 5-HT release within the PFC were affected by the OX1R, OX2R or OX1/2R antagonists. However, in addition to the monoaminergic system, orexins also activate cholinergic neurons through both OX1R and OX2R (Fadel and This article has not been copyedited and formatted. The final version may differ from this version. cataplexy, the activity of histaminergic cells is maintained whereas noradrenergic and serotonergic neurons are inactive (John et al., 2004) . Therefore, the transient reduced HA release in the LH by selective OX2R inhibition with no alteration of extracellular cortical NE and 5-HT levels is not expected to particularly favor cataplexy-like behavior.
In conclusion, these findings highlight the complex interplay between OX1R and 
